Journal of vascular surgery. Venous and lymphatic disorders · 2026
Unraveling the economics of pulmonary embolism care in a 23-year resource utilization study.
СтатьяСравнительное исследованиеНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Cuartas Pablo Alberto, Ferguson Claire, Orlov Danylo, Sihaloho Dewi, Shemtov Ron, Seckler Solomon, Sharath Sherene E, Kougias Panos
Аннотация
BACKGROUND: The systematic assessment of resource utilization in cost-intensive diseases such as pulmonary embolism (PE) is important to optimize health system efficiency. We examined the association between treatment modality, cost, and length of stay among inpatients diagnosed with PE.
METHODS: Using data from the National Inpatient Sample (1998-2021), we performed a retrospective trend analysis. Inpatient charges were converted to costs using the cost-to-charge ratio. Average cost differences between catheter-directed thrombolysis, anticoagulation, systemic thrombolysis, catheter-directed embolectomy, and surgical embolectomy were assessed using survey-weighted linear regressions, with hospital clustering. Differences in median length of stay, by treatment modality, were modeled using quantile regression.
RESULTS: The sample included 1,375,419 admissions; 1,338,332 (97.3%) received anticoagulation, 22,934 (1.7%) underwent systemic thrombolysis, 8363 (0.6%) underwent catheter-directed thrombolysis, 3453 (0.3%) underwent catheter-directed embolectomy, and 2337 (0.2%) underwent surgical embolectomy. Compared with catheter-directed thrombolysis, surgical embolectomy, catheter-directed embolectomy, and systemic thrombolysis were associated with higher average costs (surgical embolectomy, +$46,156; catheter-directed embolectomy, +$9042; systemic thrombolysis, +$3094, respectively; all P < .001); anticoagulation was less expensive ($9707 less expensive; P < .001). The median length of stay was longer after anticoagulation (+0.2 day), systemic thrombolysis (+1.4 days), and surgical embolectomy (+5.6 days; all P < .001). Catheter-directed embolectomy was associated with a shorter median length of stay (-0.6 day; P < .001).
CONCLUSIONS: Substantial cost disparities exist among PE treatment modalities, spanning thousands of dollars. Although catheter-directed embolectomy was associated with the shortest median length of stay, the least expensive treatment modality was anticoagulation and the most expensive was surgical embolectomy. These insights offer guidance for optimizing resource allocation strategies in managing this prevalent postoperative complication.
METHODS: Using data from the National Inpatient Sample (1998-2021), we performed a retrospective trend analysis. Inpatient charges were converted to costs using the cost-to-charge ratio. Average cost differences between catheter-directed thrombolysis, anticoagulation, systemic thrombolysis, catheter-directed embolectomy, and surgical embolectomy were assessed using survey-weighted linear regressions, with hospital clustering. Differences in median length of stay, by treatment modality, were modeled using quantile regression.
RESULTS: The sample included 1,375,419 admissions; 1,338,332 (97.3%) received anticoagulation, 22,934 (1.7%) underwent systemic thrombolysis, 8363 (0.6%) underwent catheter-directed thrombolysis, 3453 (0.3%) underwent catheter-directed embolectomy, and 2337 (0.2%) underwent surgical embolectomy. Compared with catheter-directed thrombolysis, surgical embolectomy, catheter-directed embolectomy, and systemic thrombolysis were associated with higher average costs (surgical embolectomy, +$46,156; catheter-directed embolectomy, +$9042; systemic thrombolysis, +$3094, respectively; all P < .001); anticoagulation was less expensive ($9707 less expensive; P < .001). The median length of stay was longer after anticoagulation (+0.2 day), systemic thrombolysis (+1.4 days), and surgical embolectomy (+5.6 days; all P < .001). Catheter-directed embolectomy was associated with a shorter median length of stay (-0.6 day; P < .001).
CONCLUSIONS: Substantial cost disparities exist among PE treatment modalities, spanning thousands of dollars. Although catheter-directed embolectomy was associated with the shortest median length of stay, the least expensive treatment modality was anticoagulation and the most expensive was surgical embolectomy. These insights offer guidance for optimizing resource allocation strategies in managing this prevalent postoperative complication.